Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Outubro 2024 - 5:10PM
Business Wire
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, granted equity awards
on October 31, 2024 (the “Grant Date”) that were previously
approved by the Compensation Committee of its Board of Directors
under Sarepta’s 2024 Employment Commencement Incentive Plan, as a
material inducement to employment to 15 individuals hired by
Sarepta in October 2024. The equity awards were approved in
accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 12,165 restricted stock
units (“RSUs”). One-fourth of the RSUs will vest yearly on each
anniversary of the Grant Date, such that the RSUs granted to each
employee will be fully vested on the fourth anniversary of the
Grant Date, in each case, subject to each such employee’s continued
employment with Sarepta on such vesting date. Employees did not
receive options to purchase shares of Sarepta’s common stock.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic
medicine for rare diseases that devastate lives and cut futures
short. We hold leadership positions in Duchenne muscular dystrophy
(DMD) and limb-girdle muscular dystrophies (LGMDs), and we
currently have more than 40 programs in various stages of
development. Our vast pipeline is driven by our multi-platform
Precision Genetic Medicine Engine in gene therapy, RNA and gene
editing. For more information, please visit www.sarepta.com or
follow us on LinkedIn, X (formerly Twitter), Instagram and
Facebook.
Internet Posting of Information
We routinely post information that may be important to investors
in the 'For Investors' section of our website at www.sarepta.com.
We encourage investors and potential investors to consult our
website regularly for important information about us.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241031524581/en/
Investor Contact: Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact: Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024